In analogy, endoradiotherapy targeting the prostate-specific membrane antigen (PSMA) is not just a treatment option for metastasized castration-resistant prostate cancer using, i.e., [177Lu]Lu-vipivotide tetraxetan (PSMA-617) [36], but also for other tumor entities. This evidence concerns the gene FOLH1 and prostate carcinoma.